Biographical Sketch
A. Michael Lincoff, MD, is Vice Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine and an interventional cardiologist in the Sydell and Arnold Miller Family Heart & Vascular Institute at Cleveland Clinic.
He supervises clinical research activities throughout the Cleveland Clinic as Director of the Center for Clinical Research of the Lerner Research Institute. Dr. Lincoff is also the Director of the Cleveland Clinic Coordinating Center for Clinical Research (C5Research), an academic research organization that plans, coordinates and manages multicenter clinical trials of new pharmacologic or device therapies.
Dr. Lincoff’s research activities focus on development of therapies to reduce acute and long-term complications of percutaneous coronary revascularization procedures, to optimize therapy for acute coronary ischemic syndromes or reduce progression or complications of atherosclerosis. He has served as principal investigator or steering committee member of over 15 pivotal trials in ischemic heart disease, enrolling in aggregate over 50,000 patients, studying new antiplatelet or antithrombotic agents in the settings of coronary intervention, heart attack or unstable angina.
Dr. Lincoff is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He holds the Charles and Charlotte Fowler Endowed Chair for Cardiovascular Research at Cleveland Clinic.
Dr. Lincoff has authored or coauthored over 200 peer-reviewed articles, including publications in the New England Journal of Medicine, Journal of the American Medical Association, Lancet, Annals of Internal Medicine, Circulation, Journal of the American College of Cardiology, American Heart Journal and European Heart Journal. He is editor of a book entitled Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, now in its second edition. He has also authored over 80 book chapters and reviews and presented over 300 lectures at various medical meetings and courses throughout the world. He is the Consulting Editor of the American Journal of Cardiovascular Drugs and serves on editorial boards or as a reviewer for over 15 peer-reviewed scientific journals.
Dr. Lincoff is currently a member of the Cardiovascular and Renal Drugs Advisory Committee of the United States Food and Drug Administration.
Dr. Lincoff is a fellow of the American College of Cardiology and the European Society of Cardiology and a member of the American College of Physicians, scientific councils of the American Heart Association and the Sigma Xi Scientific Research Society.
Specialty Interests
coronary angioplasty and stenting, treatment of unstable heart disease and myocardial infarction (heart attack)
Awards & Honors
Best Doctors, Cleveland magazine
Industry Relationships
Cleveland Clinic physicians and scientists report if they
have any collaborations with the pharmaceutical or medical
device industries as part of the Cleveland Clinic’s
procedures. The Cleveland Clinic publicly discloses
payments to its physicians and scientists for speaking and
consulting of $5,000 or more per year, and any equity,
royalties, and fiduciary relationships in companies with
which they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its doctors’
connections with industry and those of their immediate
family members. As of 8/6/2008,
Dr. Lincoff has reported no financial relationship with
industry that is applicable to this listing. Patients
should feel free to contact their doctor about
relationships with industry and how the relationships are
overseen by the Cleveland Clinic. To learn more about
the Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to our
Integrity in Innovation page.
